

MAR 11 2022

SENATE RESOLUTION

REQUESTING THE DEPARTMENT OF HEALTH TO CONVENE A THERAPEUTIC
PSILOCYBIN WORKING GROUP TO EXAMINE THE MEDICINAL AND
THERAPEUTIC EFFECTS OF PSILOCYBIN AND DEVELOP A LONG-TERM
STRATEGIC PLAN TO ENSURE THE AVAILABILITY OF MEDICINAL
PSILOCYBIN OR PSILOCYBIN-BASED PRODUCTS THAT ARE SAFE,
ACCESSIBLE, AND AFFORDABLE FOR ELIGIBLE ADULT PATIENTS.

1 WHEREAS, mental health conditions are treated in various
2 ways depending on the condition and can include medication,
3 therapy, and psychosocial services; and
4

5 WHEREAS, these treatments, while effective for certain
6 conditions and patients, do not treat all mental health
7 conditions; and
8

9 WHEREAS, psilocybin is a naturally-occurring chemical
10 compound found in certain species of mushrooms; and
11

12 WHEREAS, psilocybin can activate serotonin receptors in the
13 brain; and
14

15 WHEREAS, studies conducted by nationally and
16 internationally recognized medical institutions indicate that
17 psilocybin has shown efficacy, tolerability, and safety in the
18 treatment of a variety of mental health conditions, including
19 addiction, depression, anxiety disorders, and end-of-life
20 psychological distress; and
21

22 WHEREAS, the United States Food and Drug Administration has
23 determined that preliminary clinical evidence indicates that
24 psilocybin may demonstrate substantial improvement over
25 available therapies for treatment-resistant depression and has
26 granted a breakthrough therapy designation for a treatment that
27 uses psilocybin as a therapy for treatment-resistant depression;
28 and
29

30 WHEREAS, Hawaii has a shortage of mental health
31 professionals, and should actively consider novel, innovative,
32 and safe solutions to treat its citizens; now, therefore,



1
2 BE IT RESOLVED by the Senate of the Thirty-first
3 Legislature of the State of Hawaii, Regular Session of 2022,
4 that the Department of Health is requested to convene a
5 Therapeutic Psilocybin Working Group, to be placed within the
6 Department of Health for administrative purposes; and
7

8 BE IT FURTHER RESOLVED that the Therapeutic Psilocybin
9 Working Group is requested to examine:
10

11 (1) Federal, state, and local laws, regulations,
12 administrative rules, and procedures regarding the
13 therapeutic use of psilocybin;
14

15 (2) Available medical, psychological, and scientific
16 studies, research, and other information relating to
17 the safety and efficacy of psilocybin in treating
18 mental health conditions; and
19

20 (3) The requirements, specifications, and guidelines for a
21 medical professional to prescribe and provide
22 psilocybin to patients in jurisdictions where
23 psilocybin is approved to treat mental health
24 conditions; and
25

26 BE IT FURTHER RESOLVED that the Therapeutic Psilocybin
27 Working Group is requested to develop a long-term strategic plan
28 to ensure the availability of therapeutic psilocybin or
29 psilocybin-based products that are safe, accessible, and
30 affordable for adults twenty-one years of age or older; and
31

32 BE IT FURTHER RESOLVED that the following individuals, or
33 their respective designees, are requested to serve as members of
34 the Therapeutic Psilocybin Working Group:
35

36 (1) The Director of Health, who is requested to serve as
37 chairperson of the working group;
38

39 (2) The Attorney General;
40

41 (3) The Dean of the John A. Burns School of Medicine at
42 the University of Hawaii at Manoa;



- 1
2 (4) The chairpersons of the Senate and House of
3 Representatives standing committees whose subject
4 matter purview is primarily responsible for reviewing
5 legislation relating to health and the Judiciary;
6
7 (5) The chairperson of the Hawaii State Council on Mental
8 Health;
9
10 (6) A physician duly licensed under chapter 453, Hawaii
11 Revised Statutes, or advanced practice registered
12 nurse with the authority to prescribe psychotropic
13 medication and duly licensed under chapter 457, Hawaii
14 Revised Statutes, to be invited by the chairperson of
15 the working group; and
16
17 (7) A psychiatrist duly licensed under chapter 453, Hawaii
18 Revised Statutes, to be invited by the chairperson of
19 the working group; and
20

21 BE IT FURTHER RESOLVED that the chairperson of the
22 Therapeutic Psilocybin Working Group may invite other interested
23 parties with relevant experience to join the working group; and
24

25 BE IT FURTHER RESOLVED that the Therapeutic Psilocybin
26 Working Group is requested to submit:
27

- 28 (1) A preliminary report of its findings and
29 recommendations to the Legislature no later than
30 twenty days prior to the convening of the Regular
31 Session of 2023; and
32
33 (2) A final report of its findings and recommendations,
34 including any proposed legislation, to the Legislature
35 no later than twenty days prior to the convening of
36 the Regular Session of 2024; and
37

38 BE IT FURTHER RESOLVED that the Therapeutic Psilocybin
39 Working Group be dissolved on July 1, 2024; and
40



S.R. NO. 88

1 BE IT FURTHER RESOLVED that certified copies of this
2 Resolution be transmitted to the Director of Health, Attorney
3 General, and Dean of the John A. Burns School of Medicine.
4
5
6

OFFERED BY:

A handwritten signature in black ink, appearing to be 'C. L. ...', written over a horizontal line.